https://scholars.lib.ntu.edu.tw/handle/123456789/597107
標題: | Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia | 作者: | Grunwald M.R. LI-HUI TSENG Lin M.-T. Pratz K.W. Eshleman J.R. Levis M.J. Gocke C.D. |
關鍵字: | Acute myeloid leukemia (AML); Bone marrow transplant; FLT3; Internal tandem duplication(ITD); Minimal residual disease(MRD); Tandem duplication PCR(TD-PCR) | 公開日期: | 2014 | 出版社: | Elsevier Inc. | 卷: | 20 | 期: | 12 | 起(迄)頁: | 1989-1995 | 來源出版物: | Biology of Blood and Marrow Transplantation | 摘要: | Patients with acute myeloid leukemia (AML) who harbor internal tandem duplication (ITD) mutations of the FMS-like tyrosine kinase 3 (. FLT3) gene carry a poor prognosis. Although allogeneic transplantation may improve outcomes, relapse occurs frequently. The FLT3/ITD mutation has been deemed an unsuitable minimal residual disease (MRD) marker because it is unstable and because the standard assay for the mutation is relatively insensitive. The FLT3 mutation is undetectable by PCR at pre- or post-transplant time points in many FLT3/ITD AML patients who subsequently relapse after transplant. We report the application of a new technique, tandem duplication PCR (TD-PCR), for detecting MRD in FLT3/ITD AML patients. Between October 2004 and January 2012, 54 FLT3/ITD AML patients in remission underwent transplantation at our institution. Of 37 patients with available day 60 marrow samples, 28 (76%) were assessable for MRD detection. In seven of 28 patients (25%), the FLT3/ITD mutation was detectable by TD-PCR but not by standard PCR on day 60. Six of 7 patients (86%) with MRD by TD-PCR have relapsed to date compared with only 2 of 21 patients (10%) who were negative for MRD (. P=.0003). The ability to detect MRD by this sensitive technique may provide an opportunity for early clinical intervention. ? 2014 American Society for Blood and Marrow Transplantation. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84912080352&doi=10.1016%2fj.bbmt.2014.08.015&partnerID=40&md5=80dbbe8028ed2c35c305d73454d88e60 https://scholars.lib.ntu.edu.tw/handle/123456789/597107 |
ISSN: | 1083-8791 | DOI: | 10.1016/j.bbmt.2014.08.015 | SDG/關鍵字: | busulfan; CD135 antigen; cyclophosphamide; fludarabine; CD135 antigen; FLT3 protein, human; acute granulocytic leukemia; adult; allotransplantation; Article; cancer patient; cancer recurrence; cancer regression; cancer survival; clinical article; controlled study; female; gene duplication; gene mutation; genetic parameters; human; internal tandem duplication; male; myeloablative conditioning; polymerase chain reaction; prediction; recurrence free survival; treatment outcome; allograft; blood; gene expression regulation; genetics; Leukemia, Myeloid, Acute; middle aged; minimal residual disease; nucleotide sequence; polymerase chain reaction; predictive value; recurrent disease; stem cell transplantation; Adult; Allografts; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutagenesis, Insertional; Neoplasm, Residual; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Stem Cell Transplantation |
顯示於: | 基因體暨蛋白體醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。